I've seen some positive examples of R/S, but those were all OTCs graduating to big boards for the first time and had lots of good news timed with the split. Off the top of my head the better ones were bio plays. R/S aren't always horrible for the stock, but even in the good scenarios they just don't tend to have the punch that I like to shoot for.
Market Data 
Markets 
AI
